Commitment to Improving Patients’ Lives
Esperion is committed to improving the lives of patients by developing therapies to lower elevated LDL-C. Esperion scientists discovered bempedoic acid (ETC-1002) and the LDL-C lowering therapy is in Phase 3 development. Esperion plans to develop both bempedoic acid and a fixed dose combination of bempedoic acid and ezetimibe with a particular focus on patients with elevated LDL-C who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.
- Respect Individual Dignity
- Commit to Vibrant Teamwork
- Inspire Colleagues to Challenge Conventional Thinking and to Innovate
- Encourage Continuous Curiosity to Achieve Excellence in Science